<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006677</url>
  </required_header>
  <id_info>
    <org_study_id>2021-TR</org_study_id>
    <nct_id>NCT05006677</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus</brief_title>
  <official_title>Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral&#xD;
      anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and&#xD;
      non-antithrombotic therapy - for the treatment of VT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 4, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombus resolution in 12 weeks follow-up</measure>
    <time_frame>12 weeks</time_frame>
    <description>Thrombus resolution in 12 weeks follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombus resolution in 6 weeks follow-up</measure>
    <time_frame>6 weeks</time_frame>
    <description>Thrombus resolution in 6 weeks follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombus resolution in 6 months follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>Thrombus resolution in 6 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombus resolution in 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Thrombus resolution in 12 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolism events</measure>
    <time_frame>12 months</time_frame>
    <description>Thromboembolism events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Ventricular Thrombus</condition>
  <arm_group>
    <arm_group_label>non-vitamin K antagonist oral anticoagulants (NOACs)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin K antagonists (VKAs)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>antiplatelet agents</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non-antithrombotic therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-vitamin K antagonist oral anticoagulants (NOACs)</intervention_name>
    <description>Collecting information of patients with VT who received NOACs</description>
    <arm_group_label>non-vitamin K antagonist oral anticoagulants (NOACs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin K antagonists (VKAs)</intervention_name>
    <description>Collecting information of patients with VT who received VKAs</description>
    <arm_group_label>vitamin K antagonists (VKAs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiplatelet agents</intervention_name>
    <description>Collecting information of patients with VT who received antiplatelet agents</description>
    <arm_group_label>antiplatelet agents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-antithrombotic therapy</intervention_name>
    <description>Collecting information of patients with VT without any antithrombotic therapy</description>
    <arm_group_label>non-antithrombotic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had a diagnosis of VT in Fuwai Hospital, National Center of Cardiovascular&#xD;
        Diseases in China from July 2010 through October 2019.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with ventricular thrombus(VT), regardless of sex, basic diseases, occupation or&#xD;
             education;&#xD;
&#xD;
          -  The VT should be found newly within 3 months;&#xD;
&#xD;
          -  The observational phase should last until the time that patients who had achieved&#xD;
             thrombus resolution. The following up period after the phase ended should continue for&#xD;
             at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals received standard antithrombotic therapy within 4 weeks;&#xD;
&#xD;
          -  Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart&#xD;
             transplantation within 6 weeks since the VT was found in the first time;&#xD;
&#xD;
          -  Had a long history of VT more than three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Qing Yang</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Yang</last_name>
      <phone>+86 01088322797</phone>
      <email>sunnydog1028@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gianstefani S, Douiri A, Delithanasis I, Rogers T, Sen A, Kalra S, Charangwa L, Reiken J, Monaghan M, MacCarthy P. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol. 2014 Apr 1;113(7):1111-6. doi: 10.1016/j.amjcard.2013.12.015. Epub 2014 Jan 14.</citation>
    <PMID>24485697</PMID>
  </reference>
  <reference>
    <citation>Turpie AG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352-7.</citation>
    <PMID>2643772</PMID>
  </reference>
  <reference>
    <citation>Abdelnaby M, Almaghraby A, Abdelkarim O, Saleh Y, Hammad B, Badran H. The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol. 2019 Jan;21(1):47-50. doi: 10.14744/AnatolJCardiol.2018.48313.</citation>
    <PMID>30587707</PMID>
  </reference>
  <reference>
    <citation>Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Bl√∂mstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.</citation>
    <PMID>22922416</PMID>
  </reference>
  <reference>
    <citation>He J, Ge H, Dong JX, Zhang W, Kong LC, Qiao ZQ, Zheng Y, Ding S, Wan F, Shen L, Wang W, Gu ZC, Yang F, Li Z, Pu J. Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). Ann Transl Med. 2020 Mar;8(6):392. doi: 10.21037/atm.2020.02.117.</citation>
    <PMID>32355836</PMID>
  </reference>
  <reference>
    <citation>Guddeti RR, Anwar M, Walters RW, Apala D, Pajjuru V, Kousa O, Gujjula NR, Alla VM. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020 Dec;133(12):1488-1491. doi: 10.1016/j.amjmed.2020.05.025. Epub 2020 Jun 27.</citation>
    <PMID>32598904</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

